Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 244-252

  Fukazawa, Takuya ^a   Maeda, Yutaka ^b   Durbin, Mary L ^c   Nakai, Toru ^a   Matsuoka, Junji ^a   Tanaka, Hirotoshi ^d   Naomoto, Yoshio ^a   Tanaka, Noriaki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PROTEIN BAX; SURFACTANT PROTEIN A; TELOMERASE; THYROID TRANSCRIPTION FACTOR 1;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CELL DEATH; CELL TYPE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; GENE INSERTION; HUMAN; HUMAN CELL; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STEM CELL; TISSUE SPECIFICITY;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CELL DEATH; CELL LINE, TUMOR; DEXAMETHASONE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLUCOCORTICOIDS; HUMANS; LUNG NEOPLASMS; MICE; ORGAN SPECIFICITY; PROMOTER REGIONS (GENETICS); PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; RNA, MESSENGER; STEM CELLS; TRANSCRIPTION, GENETIC;

EID: 33846818556     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0408     Document Type: Article

References (47)

1. Pulkkanen KJ, Parkkinen JJ, Laukkanen JM, et al. HSV-tk gene therapy for human renal cell carcinoma in nude mice. Cancer Gene Ther 2001;7: 529-36.
2. Lemoine NR, McNeish IA. Gene transfer: Bax to the future for cancer therapy. Gut 2004;4:479-87.
3. Lee HW, Blasco MA, Gottlieb GJ, et al. Essential role of mouse telomerase in highly proliferative organs. Nature 1998;392:569-74.
4. Thomson, JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-7.
5. Golubovskaya VM, Filatov LV, Behe CI, et al. Telomere shortening, telomerase expression and chromosome instability in rat hepatic epithelial stem-like cells. Mol Carcinog 1999;24:209-17.
6. Youssef N, Paradis V, Ferlicot S, Bedossa P. In situ detection of telomerase enzymatic activity in human hepatocellular carcinogenesis. J Pathol 2001;194:459-65.
7. Kotoula V, Hytiroglou P, Pyrpasopoulou A, et al. Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver 2002;22:57-69.
8. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2002;2:257-65.
9. Ikeda K, Clark JC, Shaw-White JR, et al. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J Biol Chem 1995;270:8108-14.
10. Stahlman MT, Gray ME, Whitsett JA. Expression of thyroid transcription factor-1(TTF-1) in fetal and neonatal human lung. J Histochem Cytochem 1996;44:673-8.
11. Bohinski RJ, Di Lauro R, Whitsett JA. The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol Cell Biol 1994;14:5671-81.
12. Bruno MD, Bohinski RJ, Huelsman KM, Whitsett JA, Korfhagen TR. Lung cell-specific expression of the murine surfactant protein A (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1. J Biol Chem 1995;270:6531-6.
13. Fukazawa T, Maeda Y, Sladek FM, Owen-Schaub LB. Development of a cancer-targeted tissue-specific promoter system. Cancer Res 2004;64: 363-9.
14. Hoover RR, Thomas KH, Floros J. Glucocorticoid inhibition of human SP-A1 promoter activity in NCI-H441 cells. Biochem J 1999;340:69-76.
15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
16. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-500.
17. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications. Cancer Res 2004;64:8919-23.
18. Tracy S, Mukohara T, Hansen M, et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64:7241-4.
19. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
20. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
21. Meijerink JP, Mensink EJ, Wang K, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998;91: 2991-7.
22. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 5:2509-14.
23. Yamane H, Kiura K, Tabata M, et al. Small cell lung cancer can express CD34 antigen. Anticancer Res 1997;17:3627-32.
24. Aoe K, Kiura K, Ueoka H, et al. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res 1999;19:291-9.
25. Kawai H, Kiura K, Tabata M, et al. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 2002;3:305-14.
26. Kohara H, Tabata M, Kiura K, et al. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin Cancer Res 2002;1:287-92.
27. Yi M, Tong GX, Murry B, Mendelson CR. Role of CBP/p300 and SRC-1 in transcriptional regulation of the pulmonarysurfactant protein-A (SP-A) gene by thyroid transcription factor-1 (TTF-1). J Biol Chem 2002;277: 2997-3005.
28. Wright W, Tesmer VM, Huffman KE, Levene SD, Shay JW. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev 1997;21:2801-9.
29. Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999;59:551-7.
30. Forsyth NR, Wright WE, Shay JW. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation 2002;69:188-97.
31. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;5687:1163-7.
32. Jurgensmeier JM, Xie Z, Deveraux Q, et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 1998;95:4997-5002.
33. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999;59:1693-700.
34. Kagawa S, Gu J, Swisher SG, et al. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res 2000;60:1157-61.
35. Li X, Marani M, Yu J, et al. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res 2001;61:186-91.
36. Fukazawa T, Walter B, Owen-Schaub LB. Adenoviral Bid over-expression induces caspase-dependent tBid cleavage and p53-independent apoptosis in human non-small cell lung cancers. J Biol Chem 2003; 278:25428-34.
37. Nakase M, Inui M, Okumura K, et al. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol Cancer Ther 2005;4:625-31.
38. Khoor A, Whitsett JA, Stahlman MT, Olson SJ, Cagle PT. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 1999;30:695-700.
39. Weaver TE, Ross G, Daugherty C, Whitsett JA. Synthesis of surfactant-associated protein, 35,000 daltons, in fetal lung. J Appl Physiol 1986;61:694-700.
40. Gazdar AF, Linnoila RI, Kurita Y, et al. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res 1990;50: 5481-7.
41. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003;63: 2649-57.
42. Gordon GJ, Rockwell GN, Jensen RV, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005;66: 1827-40.
43. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006;13:830-44.
44. Check E. Second cancer case halts gene-therapy trials. Nature 2003; 421:305.
45. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005;6:299-310.
46. Pringle IA, Raman S, Sharp WW, et al. Detection of plasmid DNA vectors following gene transfer to the murine airways. Gene Ther 2005; 12:1206-14.
47. Maeda Y, Hunter TC, Loudy DE, et al. PARP-2 interacts with TTF-1 and regulates expression of surfactant protein-B. J Biol Chem 2006;281: 9600-6.